Answer:
It is important to understand that Nivolumab is a programmed cell death protein-1 (PD-1) blocking antibody used in cancer treatment. It can cause immune-related adverse events, such as diarrhea. The management of immune-related diarrhea depends on the grade of the diarrhea. The initial dose of corticosteroids for a patient who is experiencing grade 2 diarrhea due to nivolumab treatment is 1 to 2 mg/kg/day of prednisone or an equivalent corticosteroid.
This initial dose should be continued for 5 to 7 days, then tapered over the course of 2 to 4 weeks. If the diarrhea persists or worsens, the dose of corticosteroids may need to be increased or the patient may need to be hospitalized for intravenous corticosteroids and supportive care.